Accesswire
08 Dec 2025, 21:15 UTC · 41w ago
Verdict
Headline leans bullish. We score JAGX +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Initial trial results for crofelemer in infants with microvillus inclusion disease (MVID) show a parenteral support reduction of up to 37% and potential to extend lives.
So whatPositive efficacy data in a disease with no approved treatments creates a significant new catalyst for the company's valuation.
More positive than 93% of claims this week
Jaguar Health has met with the FDA to discuss a possible expedited approval pathway for crofelemer for the treatment of MVID.
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Proof-of-concept trial results for crofelemer in MVID patients are associated with toxicity.
More negative than 78% of claims this week
Stockholders approved all three proposals at the December 8, 2025, Special Meeting.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Positive news regarding stockholder approval of all proposals and promising trial results for crofelemer in treating MVID.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
−98.8%
Price is moving against the score
$7.06 vs $577.50 close before publication (Dec 8) · not market-adjusted
JAGX chart →
